Abstract
Introduction Cervarix® and Gardasil® are two HPV vaccines with differing antigen and adjuvant compositions. Gardasil-4 contains HPV types 6, 11, 16 and 18 type-specific L1 viral like particles (VLPs) formulated with amorphous AlHO9PS-3 adjuvant, while Cervarix targets HPV types 16 and 18 using AS04 (Al(OH)3 + TLR4 agonist MPL) to enhance immune response and cross-protection against other high-risk HPV types, not included in the vaccine.
Methods To investigate mechanisms of cross-neutralizing potential of Cervarix, six monozygotic twins (12 females aged 9-13 years) were vaccinated with either Cervarix or Gardasil-4 (2 doses, 6 months apart). Serum neutralizing antibody titers against HPV 6,16,18,31,33,45,52, and 58, were assessed pre-vaccination and 7 days post-second dose. Multi-omic single cell RNA and ATAC sequencing of PBMCs were performed at the latter timepoint.
Results Cervarix generated higher cross-neutralizing antibody titers than Gardasil-4. Higher frequencies of plasmacytoid (pDC) and conventional dendritic cells (cDC1, cDC2), CD4+ T effector memory (Tem) and B memory cells were also observed after Cervarix. Cervarix-vaccinated subjects showed increased DC-to-CD4+ Tem and B memory cell signaling, through increased antigen presentation and upregulation of NOTCH pathway. Gene Set Enrichment Analysis indicated enhanced pathways related to cell migration and NOTCH2 signaling in DCs and cell cycling/RNA translation in CD4+ T and B cells, correlating positively with cross-neutralizing antibody titers. Increased chromatin accessability in genes related to NOTCH signaling in cDC1 was also observed. Engagement of MHC and NOTCH induced FOS in CD4+ Tem cells and BCL2 in B memory cells, supporting proliferative and anti-apoptotic states. This also resulted in an increase in Th2 cells in Cervarix-vaccinated subjects, and increased IgG4 expression in B memory cells.
Conclusion Increased DC signaling, including NOTCH, through AS04 in Cervarix supports cell survival and sustained RNA translation in adaptive immune cells, 7 days post-vaccination, especially memory T and B cells. This increased cell metabolism and activation may enhance cell maturation of adaptive immune cells, providing a mechanism triggered by Cervarix that can lead to improved cross-reactivity.
Competing Interest Statement
G.L.-R. provided consulting services and received consulting fees from Virometix, Osivax, ICON Genetics, Sumitomo Pharma, Curevo, and Minervax. I.L.-R. declares that her institution received funding from GSK, Icosavax, Virometix, Janssen Vaccines, Curevac, Moderna, Osivax, MSD, ICON Genetics, and OSE Immunotherapeutics for other vaccine trials; and from Janssen Vaccines and MSD for consulting services. All others declare no conflicts of interest.
Clinical Trial
NCT01914367
Funding Statement
VDO has received a travel grant (V476023N) from FWO (Flanders Research Foundation) for his stay at Emory University to conduct the single-cell RNA sequencing experiments and analyses.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of Ghent University Hospital and by the Belgian Federal Agency for Medicines and Health Products (FAHMP)(EudraCT: 2013-002340-90, NCT 01914367).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author [VDO]. The data are not publicly available due to them containing information that could compromise research participant privacy.
